30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world.
Royalty Pharma Plc (RPRX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Adage Capital Management Phill Gross And Robert Atchinson | 10,896,931 | $306,094,792 | +11% | 0.63% |
| 2. | Viking Global Andreas Halvorsen | 10,087,417 | $283,355,544 | +7% | 1.03% |
| 3. | Suvretta Capital Management Aaron Cowen | 3,887,702 | $109,205,549 | -6% | 4.93% |
| 4. | GLG Partners Noam Gottesman | 2,579,152 | $72,448,380 | 0.2% | |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 2,001,100 | $56,210,899 | +1% | 0.13% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $29.51 | 130,000 | Large Shareholder, Officer, Director | 600,000 | 2023-06-28 | Filing | |
| $32.78 | 45,000 | Large Shareholder, Officer, Director | 470,000 | 2023-06-13 | Filing | |
| $33.00 | 45,000 | Large Shareholder, Officer, Director | 425,000 | 2023-06-12 | Filing | |
| $32.25 | 150,000 | Large Shareholder, Officer, Director | 380,000 | 2023-05-24 | Filing | |
| $32.94 | 69,612 | Large Shareholder, Officer, Director | 230,000 | 2023-05-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $27.55 | 35,702 | Director | 20,099 | 2024-01-04 | Filing | |
| $27.79 | 199,098 | Director | 55,801 | 2024-01-03 | Filing | |
| $28.52 | 235,200 | Director | 254,899 | 2024-01-02 | Filing | |
| $28.04 | 65,803 | 2,477,520 | 2023-12-29 | Filing | ||
| $28.20 | 209,863 | 2,543,323 | 2023-12-28 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 46,354,266 | $1,302,091,425 | 0.11% | |
| 2. | 37,997,522 | $1,067,350,392 | 0.02% | |
| 3. | 31,583,929 | $887,192,558 | 0.06% | |
| 4. | 21,459,462 | $602,796,290 | 0.01% | |
| 5. | 17,590,450 | $494,115,741 | 0.4% |
News See All
5 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
In this article, we discuss 5 most undervalued biotech stocks to buy according to hedge funds.
Royalty Pharma plc (NASDAQ:RPRX) Q4 2023 Earnings Call Transcript
Royalty Pharma plc beats earnings expectations. Reported EPS is $1.15, expectations were $1.01.
What Makes Royalty Pharma plc (RPRX) a Compelling Stock?
Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” fourth quarter 2023 investor letter. A copy of the same can be downloaded here.
13 Most Promising Future Stocks To Buy According To Hedge Funds
In this piece, we will take a look at the 13 most promising stocks to buy according to hedge funds.
5 Most Promising Healthcare Stocks According to Analysts
In this article, we discuss the 5 most promising healthcare stocks according to analysts.
Should You Sell Royalty Pharma plc (RPRX)?
TimesSquare Capital Management, an equity investment management company, released its “U.S. Mid Cap Growth Strategy” third-quarter investor letter. A copy of the same can be downloaded here.
11 Most Promising Biotech Stocks to Buy According to Analysts
In this article, we will take a look at the 11 most promising biotech stocks to buy according to analysts.
5 Stocks with 50% Upside Potential According to Analysts
In this article, we will take a look at 5 stocks with 50% upside potential according to analysts.
Royalty Pharma plc (NASDAQ:RPRX) Q3 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma Third Quarter 2023 Earnings Conference Call.
Billionaire Hedge Funds
